The stock has a 36-month beta value of 1.32. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLBT is 108.96M, and at present, short sellers hold a 0.98% of that float. On June 20, 2025, the average trading volume of CLBT was 1.24M shares.
CLBT) stock’s latest price update
Cellebrite DI Ltd (NASDAQ: CLBT)’s stock price has dropped by -2.38 in relation to previous closing price of 15.98. Nevertheless, the company has seen a loss of -3.47% in its stock price over the last five trading days. globenewswire.com reported 2025-06-05 that Combination Delivers Unmatched Innovation in Arm-based Vulnerability and Malware Research, Smart Device DevSecOps and Mobile Pen Testing Combination Delivers Unmatched Innovation in Arm-based Vulnerability and Malware Research, Smart Device DevSecOps and Mobile Pen Testing
CLBT’s Market Performance
Cellebrite DI Ltd (CLBT) has experienced a -3.47% fall in stock performance for the past week, with a -8.34% drop in the past month, and a -17.94% drop in the past quarter. The volatility ratio for the week is 1.91%, and the volatility levels for the past 30 days are at 1.49% for CLBT.. The simple moving average for the past 20 days is -5.46% for CLBT’s stock, with a -18.84% simple moving average for the past 200 days.
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the previous year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the previous year.
CLBT Trading at -13.29% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLBT starting from DAVID GEE, who proposed sale 12,150 shares at the price of $16.71 back on May 23 ’25. After this action, DAVID GEE now owns shares of Cellebrite DI Ltd, valued at $203,026 using the latest closing price.
DAVID GEE, the OFFICER of Cellebrite DI Ltd, proposed sale 10,555 shares at $17.05 during a trade that took place back on May 21 ’25, which means that DAVID GEE is holding shares at $179,963 based on the most recent closing price.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.46. The total capital return value is set at 0.14. Equity return is now at value -115.35, with -31.35 for asset returns.
Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 13.49. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 0.23.
Currently, EBITDA for the company is 67.51 million with net debt to EBITDA at -1.13. When we switch over and look at the enterprise to sales, we see a ratio of 8.72. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
To sum up, Cellebrite DI Ltd (CLBT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
